ADVA-OPTICAL-NETWORKING
14.10.2021 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that i3D.net has deployed its FSP 3000 TeraFlex™ to enhance the experience of the 50 million online gamers that i3D.net serves every day. The technology enables the leading hosting solutions provider for the gaming industry to meet rising data demand and customer expectation by significantly increasing capacity and reducing latency in its global transport network. ADVA’s highly flexible solution enables i3D.net to harness previously unused spectrum, optimizing all optical paths and unlocking new value in its existing fiber infrastructure. The TeraFlex™ terminal will also benefit i3D.net’s enterprise customers, who will be able to leverage low-latency video conferencing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005058/en/
“As one of the world’s leading high-performance hosting providers, we’re constantly striving to deliver an unbeatable experience for end users. That means investing in the most advanced technology on the market. With our new infrastructure built on the ADVA FSP 3000 TeraFlex™ , we’re removing any bottlenecks by massively increasing the capacity of our network. And, thanks to its ultra-flexible coherent interfaces with fractional QAM, it ensures maximum data throughput over every link,” said Edwin Verwoerd, VP, engineering, i3D.net. “Low latency is our business, and that’s precisely what our new solution offers. It enables us to provide a winning edge to both players and businesses.“
i3D.net’s specific configuration of the ADVA FSP 3000 TeraFlex™ is able to carry up to 400Gbit/s of data per wavelength and 800Gbit/s per sled. This open and ultra-flexible 1RU terminal uses software-defined fractional QAM modulation and adaptive baud rate capabilities. As well as significantly boosting the capacity of i3D.net’s worldwide infrastructure, the ADVA FSP 3000 TeraFlex™ ensures the lowest cost per bit for every fiber path. What’s more, it offers advanced streaming telemetry. This provides operators with real-time performance data, helping them to ensure the highest levels of availability and quality of service for end users. The new solution also features other components of ADVA’s FSP 3000 open optical transport solution , including FSP 3000 QuadFlex™ optical terminals.
“Our FSP 3000 TeraFlex™ will be a vital tool for i3D.net. It will be key to seizing new opportunities during the global gaming boom and providing unprecedented levels of quality for its customers. The innovative terminal offers excellent space- and power-efficiency while maximizing fiber utilization. With its flexible bandwidth modulation, it ensures optimal performance even over long-distance links. That’s why our high-performance TeraFlex™ is ideal for supporting satisfying, immersive gaming,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “It’s great to see another major operator harnessing our TeraFlex™ technology to unlock extra value in its infrastructure. Spread across six continents, i3D.net’s network will now deliver even more for its customers.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About i3D.net
i3D.net – a Ubisoft company, is one of the leading providers of high-performance hosting and global infrastructure services. We operate a global low-latency network with thousands of servers spread over 40+ point of presence on 6 continents. i3D.net excels in the gaming market and hosts a variety of AAA games. Our mission is to bring the lowest latency to as many users around the world as possible, with the goals of reaching 1 billion users on our platforms by 2025. For more information visit www.i3d.net .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005058/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom